JAK2V617F mutation in immune thrombocytopenia

Thromb Res. 2016 Aug:144:149-51. doi: 10.1016/j.thromres.2016.06.019. Epub 2016 Jun 17.

Authors

Cih-En Huang¹, Yi-Yang Chen¹, Jing-Lan Liu², Hsing-Ying Ho¹, Chian-Pei Li¹, Chih-Cheng Chen³

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
² Department of Pathology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
³ Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan; College of Medicine, Chang Gung University, Tao-Yuan, Taiwan. Electronic address: ccchen1968@gmail.com.

PMID: 27344349
DOI: 10.1016/j.thromres.2016.06.019

No abstract available

Keywords: Essential thrombocythemia; Immune thrombocytopenic purpura; JAK2V617F mutation; Myeloproliferative neoplasm.

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Anti-Inflammatory Agents / therapeutic use
Dexamethasone / therapeutic use
Female
Humans
Janus Kinase 2 / genetics*
Platelet Count
Point Mutation*
Purpura, Thrombocytopenic, Idiopathic / blood
Purpura, Thrombocytopenic, Idiopathic / drug therapy
Purpura, Thrombocytopenic, Idiopathic / genetics*
Purpura, Thrombocytopenic, Idiopathic / surgery
Spleen / surgery
Splenectomy

Substances

Anti-Inflammatory Agents
Dexamethasone
JAK2 protein, human
Janus Kinase 2